Iovance Shares Jump Over 20% After 50% Response Rate in Soft-Tissue Sarcoma Trial
Iovance Biotherapeutics shares surged over 20% after its lifileucel monotherapy pilot trial in advanced soft-tissue sarcomas delivered a 50% confirmed objective response among six evaluable patients. The company will launch a single-arm registrational trial in Q2 2026 and expects to target over 8,000 U.S. and European patients annually.
1. Positive Pilot Trial Results
Iovance’s pilot study of lifileucel monotherapy in patients with advanced undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma achieved a 50% confirmed objective response rate among the first six evaluable subjects. The trial was conducted at Memorial Sloan Kettering Cancer Center in patients refractory to prior therapies, marking a potential breakthrough in treatment efficacy.
2. Registrational Trial and Market Potential
Following these results, Iovance plans to initiate a single-arm registrational trial in the second quarter of 2026 and engage the FDA for expedited review. The company projects a U.S. and European market of more than 8,000 annual diagnoses and intends to explore lifileucel in additional high-grade soft-tissue sarcoma subtypes.